Opinion|Videos|August 30, 2024
Advice for States that Require Prior Prescriber Approval for Substitution
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys gives advice for states that require prior prescriber approval for substitution.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can pharmacists navigate states with stringent regulations on switching from biologics to biosimilars? For example, in Alabama, pharmacists cannot substitute an interchangeable biosimilar for the originator biologic without prior prescriber approval.
Advertisement
Related to this article
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
New warnings cover every GLP-1 RA, including semaglutide, tirzepatide, and orforglipron.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
3
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
4
How Pharmacists Help Patients Spot Patterns in Glucose Readings
5